Ad is loading...
HGHTX vs JNGLX
HGHTX vs JNGLX Comparison Chart
Loading...
View a ticker or compare two or three
VS
VS
HGHTX vs. JNGLX commentary
Dec 19, 2024
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HGHTX is a Buy and JNGLX is a Buy.
FUNDAMENTALS
Fundamentals
JNGLX has more cash in the bank: 5.25B vs. HGHTX (952M). JNGLX pays higher dividends than HGHTX: JNGLX (0.12) vs HGHTX (0.00). HGHTX was incepted earlier than JNGLX: HGHTX (18 years) vs JNGLX (26 years). JNGLX is a more actively managed with annual turnover of: 34.00 vs. HGHTX (32.00). HGHTX has a lower initial minimum investment than JNGLX: HGHTX (0) vs JNGLX (2500). JNGLX annual gain was more profitable for investors over the last year : 4.53 vs. HGHTX (0.46). JNGLX return over 5 years is better than : 19.08 vs. HGHTX (0.37).
| HGHTX | JNGLX | HGHTX / JNGLX | |
| Total Expense Ratio | N/A | N/A | - |
| Annual Report Gross Expense Ratio | N/A | N/A | - |
| Fund Existence | 18 years | 26 years | - |
| Gain YTD | -1.989 | 1.532 | -130% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 0 | 2500 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 952M | 5.25B | 18% |
| Annual Yield % from dividends | 0.00 | 0.12 | - |
| Returns for 1 year | 0.46 | 4.53 | 10% |
| Returns for 3 years | -8.50 | -4.39 | 194% |
| Returns for 5 years | 0.37 | 19.08 | 2% |
| Returns for 10 years | 9.11 | 35.82 | 25% |
View a ticker or compare two or three
VS
VS
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| EDV | 71.85 | 0.51 | +0.71% |
| Vanguard Extended Duration Trs ETF | |||
| TPYP | 34.16 | -0.20 | -0.58% |
| Tortoise North American Pipeline | |||
| FJP | 51.06 | -0.35 | -0.68% |
| First Trust Japan AlphaDEX® ETF | |||
| FDCF | 39.10 | -0.30 | -0.77% |
| Fidelity Disruptive Communications ETF | |||
| CNCR | 12.66 | -0.15 | -1.20% |
| Range Cancer Therapeutics ETF | |||